L-Asparaginase (L-ASP) is a key component of therapy for acute lymphoblastic leukemia. Its mechanism of action, however, is still poorly understood, in part because of its dual asparaginase and glutaminase activities. Here, we show that L-ASP's glutaminase activity is not always required for the enzyme's anticancer effect. We first used molecular dynamics simulations of the clinically standard ...

The pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant Escherichia coli–asparaginase preparation was compared with Asparaginase medac. Thirty-two children with acute lymphoblastic leukemia were randomized to receive one of both agents at a dose of 5000 U/m2 every 3 days, for a total of 8 doses during induction treatment. The serum activity-time profile after the first...

Bacterial asparaginase (L-Asparaginase amidohydrolase, E.C. 3.5.1.1) is a selective and highly effective chemotherapeutic agent extensively used over the world in first-line treatment of acute lymphoblastic leukemia (ALL), Hodgkin disease, acute myelocytic leukemia, acute melanomonocytic leukemia, chronic lymphocytic leukemia, lymphosarcoma, reticlesarcoma and melanosarcoma (Verma et al., 2007)...

Introduction L-asparaginase is an essential chemotherapeutic agent in the therapy of acute lymphoblastic leukemia (ALL), which has led to improvement survival. In low- and middle-income countries like India, outcomes ALL are inferior compared with published literature, one causes believed be due quality bioequivalent asparaginase. Objective The following survey attempts understand practice usin...

l-Asparaginases belong to a family of amidohydrolases that catalyze the conversion of l-asparagine into l-aspartic acid and ammonia. Although bacterial l-asparaginases have been used extensively as anti-leukemic agents, their possible role as potential drug targets for pathogenic organisms has not been explored. The presence of genes coding for putative l-asparaginase enzymes in the Leishmania ...

i.-Asparaginase is a chemotherapeutic agent that is also immunosuppressive, inhibiting both the cellular and hu moral responses. This study deals with the effects of the enzyme on lymphocyte surface receptors to the mitogen concanavalin A. We previously reported that short incu bation of lymphocytes with L-asparaginase leads to a de creased binding of the mitogen to their surface. We now re por...

l-Asparaginase II was synthesized at constant rates by Escherichia coli under anaerobic conditions. The enzyme was produced optimally by bacteria grown between pH 7 and 8 at 37 C. Although some enzyme was formed aerobically, between 100 and 1,000 times more asparaginase II was produced during anaerobic growth in media enriched with high concentrations of a variety of amino acids. Bacteria grown...

Background L-asparaginase II (asnB), a periplasmic protein commercially extracted from E coli and Erwinia, is often used to treat acute lymphoblastic leukemia. an enzyme that converts L-asparagine aspartic acid ammonia. Cancer cells are dependent on asparagine other sources for growth, when these deprived of by the action enzyme, cancer selectively die. Objective Questions remain as whether asn...

l-Asparaginase is a key therapeutic agent for treatment of childhood acute lymphoblastic leukemia (ALL). There is wide individual variation in pharmacokinetics, and little is known about its metabolism. The mechanisms of therapeutic failure with l-asparaginase remain speculative. Here, we now report that 2 lysosomal cysteine proteases present in lymphoblasts are able to degrade l-asparaginase. ...

PURPOSE To prospectively use MRI in the early detection of intracranial sino-venous thrombosis during the L-asparaginase induction therapy of acute leukemia thus preventing the evolution of brain venous infarct. MATERIAL AND METHODS The study population consisted of seventy patients receiving L-asparaginase induction therapy for acute leukemia in the National Cancer Institute of Cairo Univers...